BNR vs. GTH, SERA, BDSX, PSNL, ENZ, RNLX, XGN, PMD, DMTK, and BGLC
Should you be buying Burning Rock Biotech stock or one of its competitors? The main competitors of Burning Rock Biotech include Genetron (GTH), Sera Prognostics (SERA), Biodesix (BDSX), Personalis (PSNL), Enzo Biochem (ENZ), Renalytix (RNLX), Exagen (XGN), Psychemedics (PMD), DermTech (DMTK), and BioNexus Gene Lab (BGLC).
Burning Rock Biotech (NASDAQ:BNR) and Genetron (NASDAQ:GTH) are both small-cap business services companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, media sentiment, valuation, dividends, community ranking, risk and profitability.
Burning Rock Biotech has higher earnings, but lower revenue than Genetron.
Burning Rock Biotech has a beta of 0.18, meaning that its stock price is 82% less volatile than the S&P 500. Comparatively, Genetron has a beta of 0.51, meaning that its stock price is 49% less volatile than the S&P 500.
Genetron has a net margin of 0.00% compared to Burning Rock Biotech's net margin of -113.39%. Genetron's return on equity of 0.00% beat Burning Rock Biotech's return on equity.
30.0% of Burning Rock Biotech shares are owned by institutional investors. Comparatively, 10.7% of Genetron shares are owned by institutional investors. 30.3% of Burning Rock Biotech shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
In the previous week, Burning Rock Biotech had 10 more articles in the media than Genetron. MarketBeat recorded 10 mentions for Burning Rock Biotech and 0 mentions for Genetron. Burning Rock Biotech's average media sentiment score of 0.40 beat Genetron's score of 0.00 indicating that Burning Rock Biotech is being referred to more favorably in the media.
Burning Rock Biotech received 3 more outperform votes than Genetron when rated by MarketBeat users. However, 33.33% of users gave Genetron an outperform vote while only 31.25% of users gave Burning Rock Biotech an outperform vote.
Summary
Genetron beats Burning Rock Biotech on 7 of the 13 factors compared between the two stocks.
Get Burning Rock Biotech News Delivered to You Automatically
Sign up to receive the latest news and ratings for BNR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BNR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Burning Rock Biotech Competitors List
Related Companies and Tools
